Improvements in identifying and diagnosing psoriatic arthritis (PsA), a chronic inflammatory arthropathy, are increasing the number of diagnosed cases in the seven major markets (7MM*), according to GlobalData, a leading data analytics company.
The company’s latest report, PsA: Epidemiology Forecast to 2028, reveals that more than 1.4 million adults are expected to be diagnosed with PsA in the 7MM by 2028, which is up from 1.1 million in 2018.
Topias Lemetyinen, Managing Epidemiologist at GlobalData, comments: “Although historically a difficult disease to diagnosis, due to limited recognition, the heterogeneity of symptoms, and similarities to other arthropathies, the recently established CASPAR diagnostic criteria is enabling doctors to improve diagnosis of PsA in patients that show symptoms.
“Improving diagnosis of PsA will continue to allow more cases of the disease to be diagnosed that may have been missed prior to the wide adoption of the CASPAR diagnostic tool.”
“PsA is a major concern for patients with psoriasis, affecting up to 30% of those with the skin condition. PsA can be a debilitating disease, causing severe joint stiffness and pain if left undiagnosed and untreated.”
*7MM: The US, France, Germany, Italy, Spain, the UK and Japan